Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This patient did not experience any complications during surgery or after the surgery, however, the patient was required to wait over 10 months for the surgery and it cost nearly USD 1 million [75].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [75]
Citations
Cites
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Palejwala, N. V., Jia, Y., Gao, S. S., Liu, L., Flaxel, C. J., Hwang, T. S., Lauer, A. K., Wilson, D. J., Huang, D., & Bailey, S. T. (2015) · Retina · doi:10.1097/iae.0000000000000867 · Cited by 165
Chau, M. J., Deveau, T. C., Song, M., Gu, X., Chen, D., & Wei, L. (2014) · Stem Cells · doi:10.1002/stem.1802 · Cited by 91
Research works printed but not linked: 1
- Seaton AD, 1992, Invest Ophthalmol Vis Sci, 33, 83
Cited by
Induced pluripotent stem cells in disease modelling and drug discovery
Rowe, R. G., & Daley, G. Q. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0100-z · Cited by 670
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A., Zekiy, A. O., Hamza, M. U., Al-Dabbagh, K. A., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 429
“The results of studies have revealed the regenerative ability of iPSCs in preclinical setting and conducted the first clinical study for treatment of age-associated with macular deterioration [10, 11].”
BackgroundBloor, A. J. C., Patel, A., Griffin, J. E., Gilleece, M. H., Radia, R., Yeung, D. T., Drier, D., Larson, L. S., Uenishi, G. I., Hei, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1050-x · Cited by 284
Advances in stem cell research and therapeutic development
De Luca, M., Aiuti, A., Cossu, G., Parmar, M., Pellegrini, G., & Robey, P. G. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0344-z · Cited by 239
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2024.12.005 · Cited by 196
Takagi, S. T., Mandai, M., Gocho, K., Hirami, Y., Yamamoto, M., Fujihara, M., Sugita, S., Kurimoto, Y., & Takahashi, M. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.04.021 · Cited by 161
Thompson, O., von Meyenn, F., Hewitt, Z., Alexander, J. J., Wood, A., Weightman, R., Gregory, S., Krueger, F., Andrews, S., Barbaric, I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15271-3 · Cited by 152
Wang, L.-T., Liu, K.-J., Sytwu, H.-K., Yen, M.-L., & Yen, B. L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.21-0021 · Cited by 131
“These concerns can be precluded with stringent QA/QC protocols to exclude undifferentiated and genetically unstable cells.(177) In addition, the functional variability with primary-isolated human samples and cell products is avoided since MSCs can be generated from a particular”
BackgroundAcquired genetic changes in human pluripotent stem cells: origins and consequences
Halliwell, J. A., Barbaric, I., & Andrews, P. W. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00292-z · Cited by 112
Towards stem cell therapies for skeletal muscle repair
Judson, R. N., & Rossi, F. M. V. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-0094-3 · Cited by 120
Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials
Wang, Y., Tang, Z., & Gu, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02955-3 · Cited by 111
Cellular regeneration strategies for macular degeneration: past, present and future
Chichagova, V., Hallam, D., Collin, J., Zerti, D., Dorgau, B., Felemban, M., Lako, M., & STEEL, D. H. (2018) · Eye · doi:10.1038/s41433-018-0061-z · Cited by 106
“Safety and tolerability have been shown and long-term cell survival suggested by graft appearance at 6 months [120].”
BackgroundiPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Attwood, S. W., & Edel, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030288 · Cited by 107
Development and application of CRISPR/Cas9 technologies in genomic editing
Zhang, C., Quan, R., & Wang, J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy120 · Cited by 86
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
Bloomer, H., Khirallah, J., Li, Y., & Xu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114087 · Cited by 78
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“This patient did not experience any complications during surgery or after the surgery, however, the patient was required to wait over 10 months for the surgery and it cost nearly USD 1 million [75].”
BackgroundPluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects
Singh, R. K., Cuzzani, O., Binette, F., Sternberg, H., West, M. D., & Nasonkin, I. O. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9802-4 · Cited by 70
Maurya, M., Bora, K., Blomfield, A. K., Pavlovich, M. C., Huang, S., Liu, C.-H., & Chen, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.369098 · Cited by 63
“In recent years, stem cell transplantation and RPE patch transplantation have shown great promise in patients with AMD (Mandai et al., 2017; Yang et al., 2022), yet safety and efficacy will await more studies.”
Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration
Kashani, A. H., LEBKOWSKI, J. S., Hinton, D. R., Zhu, D., Faynus, M. A., Chen, S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Chan, C. K., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.01.001 · Cited by 60
Selvaraj, S., Dhoke, N. R., Kiley, J., Mateos-Aierdi, A. J., Tungtur, S. K., Mondragón-González, R., Killeen, G., Oliveira, V. K. P., de Munaín, A. L., & Perlingeiro, R. C. R. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.011 · Cited by 60
Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
Rivera, T., Zhao, Y., Ni, Y., & Wang, J. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.117 · Cited by 72
Merits and challenges of iPSC-derived organoids for clinical applications
Xu, Z., Yang, J., Xin, X., Liu, C., Li, L., Mei, X., & Li, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1188905 · Cited by 64
Regenerative Medicine Applications of Mesenchymal Stem Cells
Hosseini, S., Taghiyar, L., Safari, F., & Eslaminejad, M. B. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_213 · Cited by 55
Humayun, M. S., Clegg, D., Dayan, M. S., Kashani, A. H., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Chen, S., Chan, C. K., Palejwala, N. V., et al. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.12.028 · Cited by 49
Novel Approach to Stem Cell Therapy in Parkinson's Disease
Garitaonandia, I., Gonzalez, R., Sherman, G., Semechkin, A., Evans, A. H., & Kern, R. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0001 · Cited by 48
“Derivation of iPSCs from older donors may pose the additional risk of acquiring cancer causing mutations [14,15].”
Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases
Maeda, A., Mandai, M., & Takahashi, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015043 · Cited by 55
Novoa, J. J., Westra, I. M., Steeneveld, E., Neves, N. F., Arendzen, C. H., Rajaei, B., Grundeken, E., Yildiz, M., van der Valk, W. H., Salvador, A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.02.021 · Cited by 49
Composition and Mechanism of Three-Dimensional Hydrogel System in Regulating Stem Cell Fate
Ma, J., & Huang, C. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0021 · Cited by 42
“256 Unlike scaffold-free cell delivery, where single cells or cell sheets are injected at the body site, hydrogel scaffold-based cell delivery retains cell population in a 3D structure with niche cues and relatively high mechanical compliance that can be injected or implanted as a whole system.”
Ramotowski, C., Qu, X., & Villa-Diaz, L. G. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0225 · Cited by 42
Scruggs, B. A., Jiao, C., Cranston, C. M., Kaalberg, E., Wang, K., Russell, S. R., Wiley, L. A., Mullins, R. F., Stone, E. M., Tucker, B. A., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0210 · Cited by 40
Wang, Z., Lin, Q., Yang, Y., Lu, M., Xie, K., Zhao, X., Cheung, E. H. C., Wang, Y., Jiang, X., Zhang, W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba4971 · Cited by 45
Coco, R. M., Pastor‐Idoate, S., & Jimeno, J. C. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060865 · Cited by 58
“The transplanted sheet remained intact and BCVA was stable one year after surgery, although cystoid macular edema was present [53].”
BackgroundHinkle, J. W., Mahmoudzadeh, R., & Kuriyan, A. E. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02546-9 · Cited by 47
Hsia, G. S. P., Esposito, J., Rocha, L. A., Ramos, S. L. G., & Okamoto, O. K. (2021) · Stem Cells International · doi:10.1155/2021/6632160 · Cited by 43
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Shafa, M., Yang, F., Fellner, T., Rao, M. S., & Baghbaderani, B. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00069 · Cited by 36
“Furthermore, recent progresses in the development of directed differentiation protocols using human iPSCs into various cell types (9–11) have already resulted in the start of early autologous clinical trials (12).”
BackgroundKong, A. M., Yap, K. K., Lim, S. Y., Marré, D., Pébay, A., Gerrand, Y.-W., Lees, J. G., Palmer, J. A., Morrison, W. A., & Mitchell, G. M. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.067 · Cited by 36
Petrash, C. C., Palestine, A. G., & Canto-Soler, M. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621007 · Cited by 38
“iPSC technology is currently used to create autologous RPE grafts derived from adult cells for clinical trials in Japan and the US [(8, 9, 104) and ClinicalTrials.”
BackgroundMethodInfluentialCorneal Endothelial-like Cells Derived from Induced Pluripotent Stem Cells for Cell Therapy
Ng, X. Y., Peh, G. S. L., Yam, G. H., Tay, H. G., & Mehta, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512433 · Cited by 37
“Encouragingly, a clinical trial using autologous iPSC-derived retinal epithelial cells in patients with age-related macular degeneration has been conducted [55].”
BackgroundInfluentialTsai, H., Kao, H., Kuo, M.-W., Lin, C., Chang, C.-M., Chen, Y., Chen, H., Kwok, P., Yu, A. L.-T., & Yu, J. (2023) · Nature Communications · doi:10.1038/s41467-023-40901-x · Cited by 38
Tissue engineering of the retina: from organoids to microfluidic chips
Marcos, L. F., Wilson, S. L., & Roach, P. (2021) · Journal of Tissue Engineering · doi:10.1177/20417314211059876 · Cited by 37
Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases
Yefroyev, D. A., & Jin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020208 · Cited by 40
“Indeed, preliminary clinical trials using iPSC derived cell therapy were halted due to this issue [49,79].”
BackgroundCell‐Based Therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs
Feng, L., Chao, J., Tian, E., Li, L., Ye, P., Zhang, M., Chen, X., Cui, Q., Sun, G., Zhou, T., et al. (2020) · Advanced Science · doi:10.1002/advs.202002155 · Cited by 35
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Gu, J., Wang, Y., Cui, Z., Li, H., Li, S., Yang, X., Yan, X., Ding, C., Tang, S., & Chen, J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.017 · Cited by 28
Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies
Henchcliffe, C., & Parmar, M. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181488 · Cited by 30
García-Delgado, A. B., de la Cerda, B., Amador, J. A., Valdés-Sánchez, L., Fernández‐Muñoz, B., López, M. I., Rodríguez-de-la-Rúa-Franch, E., Díez-Lloret, A., Calado, S. M., Sánchez‐Pernaute, R., et al. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2019.0007 · Cited by 29
“10 In this case report, the iPSCs were derived from skin fibroblasts of a patient with advanced wet AMD.”
The impact of transposable element activity on therapeutically relevant human stem cells
Schumann, G. G., Fuchs, N. V., Tristán-Ramos, P., Sebe, A., Ivics, Z., & Heras, S. R. (2019) · Mobile DNA · doi:10.1186/s13100-019-0151-x · Cited by 29
Rao, I., Crisafulli, L., Paulis, M., & Ficara, F. (2022) · Cells · doi:10.3390/cells11030557 · Cited by 31
“For non-hematological diseases, iPSCs for autologous cell transplantation therapy is already successfully employed in clinical trials [45].”
BackgroundNeural Cells for Neurodegenerative Diseases in Clinical Trials
Fan, Y., Goh, E. L. K., & Chan, J. K. Y. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad041 · Cited by 30
The Rise of Retinal Organoids for Vision Research
Sharma, K., Krohne, T. U., & Busskamp, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228484 · Cited by 30
(2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.01.23 · Cited by 25
Park, T. S., Zimmerlin, L., Evans-Moses, R., Thomas, J., Huo, J. S., Kanherkar, R., He, A., Ruzgar, N. M., Grebe, R. R., Bhutto, I. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14764-5 · Cited by 24
Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation
Wu, M., Mi, J., Qu, G., Zhang, S., Jian, Y., Gao, C., Cai, Q., Liu, J., Jiang, J., & Huang, H. (2024) · Cell Transplantation · doi:10.1177/09636897241244943 · Cited by 24
“They participate in innate and adaptive immune regulation 19,20 , and have been shown to inhibit the activation and proliferation of T cells 19,21 , B cells 19,22 , and natural killer (NK) cells 19,23 , as well as the migration and maturation of antigen-presenting cells (APCs) 19,24,25 .”
BackgroundStem cell therapies in cardiac diseases: Current status and future possibilities
Kasai-Brunswick, T. H., Carvalho, A. B., & de Carvalho, A. C. C. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i9.1231 · Cited by 22
Vitillo, L., Tovell, V. E., & Coffey, P. J. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1691237 · Cited by 24
iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 24
Palomo, A. B. A., Osete, J. R., Delgado‐Morales, R., Moreno‐Manzano, V., Grau‐Bové, C., Tejera, Á. M., Juan, M., Barrot, C., Santos‐Barriopedro, I., Vaquero, A., et al. (2021) · Stem Cells · doi:10.1002/stem.3358 · Cited by 22
“We demonstrate that CYCLIN D1 made iPSC have (a) lower multitelomeric signal, (b) reduced double-strand DNA breaks, (c) correct nuclear localization of RAD51 protein expression, and (d) reduced single-nucleotide polymorphism (SNP) changes per chromosome, compared with the classical reprogramming method using C-MYC.”
BackgroundMethodInfluentialShrestha, R., Wen, Y., Ding, D., & Tsai, R. (2019) · Cells · doi:10.3390/cells8010036 · Cited by 22
“In recent years, iPSCs have been extensively used for the replacement of lost photoreceptors in animal model with retinal degeneration (preclinical trials) [6–9] and clinical trials using autologous transplantation of hiPSC-derived retinal pigment epithelium (RPE) in patients with age-related macular degeneration [10].”
BackgroundKuse, Y., & Taniguchi, H. (2019) · Cell Transplantation · doi:10.1177/0963689719888459 · Cited by 22
Luciani, M., Gritti, A., & Meneghini, V. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00224 · Cited by 20
Artero‐Castro, A., Long, K. R., Bassett, A. R., Ávila‐Fernández, A., Cortón, M., Vidal‐Puig, A., Jendelová, P., Rodríguez-Jiménez, F. J., Clemente, E., Ayuso, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042092 · Cited by 21
“RPE transplants have proven successful, human embryonic stem cells (hESC) [20] or hiPSC derived RPE [21] in age-related macular degeneration patients, resulting in different outcomes.”
BackgroundStem Cell and Exosome Therapy in Pulmonary Hypertension
Oh, S., Jung, J., Ahn, K. J., Jang, A. Y., Byun, K., Yang, P. C.-M., & Chung, W. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0191 · Cited by 20
Advances in Functional Restoration of the Lacrimal Glands
Hirayama, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23528 · Cited by 17
Pluripotent stem cell-based gene therapy approach: human de novo synthesized chromosomes
Sinenko, S. A., Ponomartsev, S. V., & Tomilin, A. N. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03653-1 · Cited by 16
Regenerative medicine for the upper gastrointestinal tract
Kanetaka, K., & Eguchi, S. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.07.002 · Cited by 16
Yang, J., Chen, C., Yu, Z.-Y., Chung, J. H.-Y., Liu, X., Wu, C., & Chen, G. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100253 · Cited by 17
Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies
Beghini, D. G., Horita, S. I. M., Cascabulho, C. M., Alves, L. A., & Henriques‐Pons, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155467 · Cited by 24
Targeting cell plasticity for regeneration: From in vitro to in vivo reprogramming
Romanazzo, S., Lin, K., Srivastava, P., & Kilian, K. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.007 · Cited by 17
Two decades of induced pluripotent stem cell research: From discovery to diverse applications
Yamanaka, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.02.003 · Cited by 21
Huang, C.-S., Lin, H., Lu, K., Wu, W.-W., Yang, Y.-C., Yang, Y., Chiang, C., Hsieh, J.-H., Chang, Y., & Lee, S. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.06.002 · Cited by 13
Genetics and therapy for pediatric eye diseases
Chen, H. Y., Lehmann, O. J., & Swaroop, A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103360 · Cited by 17
Safe and stable generation of induced pluripotent stem cells using doggybone DNA vectors
Thornton, C. D., Fielding, S., Karbowniczek, K., Roig‐Merino, A., Burrows, A. E., FitzPatrick, L. M., Sharaireh, A. M., Tite, J. P., Mole, S., Harbottle, R. P., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.018 · Cited by 14
“Clinical trials to date have used a cocktail of 3 OriP/EBNA1 episomal plasmids expressing SOX2/KLF4, LIN28/L-MYC, and OCT4/shp53, respectively, to produce iPSC banks.(13) We have employed doggybone DNA (dbDNA) vectors to deliver the same 3 expression cassettes except for the absence of both OriP/EBNA1 and short hairpi…”
BackgroundMethodInfluentialLeung, J., Pollalis, D., Nair, G. K. G., Bailey, J., Pennington, B. O., Khan, A. I., Kelly, K. R., Yeh, A. K., Sundaram, K. S., Clegg, D., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.3.6 · Cited by 12
Léveillard, T., & Klipfel, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030557 · Cited by 12
Liu, Y., Sodhi, S. K., Xue, G., Teng, D., Agakishiev, D., McNally, M. M., Harris‐Bookman, S., McBride, C., Konar, G. J., & Singh, M. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.5 · Cited by 12
Mori, A., Murata, S., Tashiro, N., Tadokoro, T., Okamoto, S., Otsuka, R., Wada, H., Murata, T., Takahashi, T., Seino, K., et al. (2021) · Cells · doi:10.3390/cells10020476 · Cited by 12
“For example, studies on hiPSCs of the retina [5], myocardium [6], and neuron [7] are in progress.”
ResultMolina-Ruiz, F. J., Introna, C., Bombau, G., Galofré, M., & Canals, J. M. (2022) · Cells · doi:10.3390/cells11131984 · Cited by 15
“Indeed, one potential clinical trial of retinal pigment cells from an autologous iPSC line for age-related macular degeneration was halted once it was discovered that the cells carried a point mutation even though the significance of this particular mutation was unknown [9,17].”
BackgroundPolarized RPE Secretome Preserves Photoreceptors in Retinal Dystrophic RCS Rats
Ahluwalia, K., Martínez-Camarillo, J.-C., Thomas, B. B., Naik, A. A., Gonzalez-Calle, A., Pollalis, D., LEBKOWSKI, J. S., Lee, S. Y., Mitra, D., Louie, S. G., et al. (2023) · Cells · doi:10.3390/cells12131689 · Cited by 11
Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases
Hetta, H. F., Elsaghir, A., Sijercic, V. C., Ahmed, A. K., Gad, S. A., Zeleke, M. S., Alanazi, F. E., & Ramadan, Y. N. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70189 · Cited by 15
“Preclinical research has demonstrated the capacity of iPSCs to regenerate tissue, and the first clinical trial to treat age ‐ related macular degeneration has been conducted [20, 21].”
100 plus years of stem cell research—20 years of ISSCR
Lendahl, U. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.04.004 · Cited by 18
“AMD is accompanied by progressive loss of retinal pigment epithelial (RPE) cells, which are crucial for survival of the overlying photoreceptor cells.”
MethodInfluentialShen, H., Ding, C., Yuan, S., Pan, T. S., Li, D., Li, H., Huang, B., & Liu, Q. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.008 · Cited by 13
Huang, C.-Y., Li, L.-H., Hsu, W.-T., Cheng, Y., Nicholson, M. W., Liu, C.-L., Ting, C.-Y., Ko, H.-W., Syu, S., Wen, C.-H., et al. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00682-7 · Cited by 10
“Since its discovery, iPSC technology has become a powerful tool for understanding the correlation between patient genotype and phenotype and recently has shown promising clinical applications [25].”
BackgroundMeiser, I., Majer, J., Katsen‐Globa, A., Schulz, A., Schmidt, K., Stracke, F., Koutsouraki, E., Witt, G., Keminer, O., Pleß, O., et al. (2021) · Cryobiology · doi:10.1016/j.cryobiol.2021.09.010 · Cited by 10
Epigenetic mechanisms of Müller glial reprogramming mediating retinal regeneration
Si, T., Li, Z., Zhang, J., Su, S., Liu, Y., Chen, S., Peng, G.-H., Cao, J., & Zang, W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1157893 · Cited by 10
“Cell reprogramming technology is currently being applied to regenerate various cell types in the pancreas, heart, liver, and central nervous system and is expected to emerge as a new method for the treatment of retinal degenerative diseases (Singh et al., 2013b; Mandai et al., 2017; Waldron et al., 2018; Yao et al., 2…”
MethodRen, J., Li, C., Zhang, M., Wang, H., Xie, Y., & Tang, Y. (2021) · Cells · doi:10.3390/cells10113087 · Cited by 12
“versatile for studying the molecular biology of neural induction [2–4] and transplantationbased cell therapy [5,6], as well as modeling the pathogenesis of diseases [7–10] and drug screening [11,12].”
BackgroundQiu, C., Sun, Y., Li, J., Xu, Y., Zhou, J., Qiu, C., Zhang, S., He, Y., & Yu, L. (2022) · Bioengineering · doi:10.3390/bioengineering9100535 · Cited by 11
“However, the concerns of safety (tumorigenicity and immunogenicity) and ethics hinder clinical applications [18,19].”
BackgroundEngineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives
Li, J., Liu, L., Zhang, J., Qu, X., Kawamura, T., Miyagawa, S., & Sawa, Y. (2022) · Bioengineering · doi:10.3390/bioengineering9110605 · Cited by 14
Stem cell therapies in neurology: the good, the bad and the unknown
Lyon, L. (2018) · Brain · doi:10.1093/brain/awy221 · Cited by 10
Du, W., Cui, L., Zhang, J., Zhang, H., Liu, R., Yang, W., & Zhang, Y. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13460 · Cited by 9
Cellular and circuit remodeling of the primate foveal midget pathway after acute photoreceptor loss
Akiba, R., Boniec, S. L., Knecht, S., Uyama, H., Tu, H., Baba, T., Takahashi, M., Mandai, M., & Wong, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413104121 · Cited by 9
Shimizu, Y., Nakamura, Y., Horibata, Y., Fujimaki, M., Hayashi, K., Uchida, N., Morita, H., Arai, R., Chibana, K., Takemasa, A., et al. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.03.007 · Cited by 10
Song, Z., Xu, L., Wang, J., Rasti, R., Sastry, A., Li, J. D., Raynor, W., Izatt, J. A., Toth, C. A., Vajzovic, L. M., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.020 · Cited by 11
Wang, M., Liu, Y., Wang, Z., Qiao, L., Ma, X., Hu, L., Kong, D., Wang, Y., & Ye, H. (2022) · Advanced Science · doi:10.1002/advs.202202858 · Cited by 7
Pollalis, D., Nair, G. K. G., Leung, J., Bloemhof, C. M., Bailey, J., Pennington, B. O., Kelly, K. R., Khan, A. I., Yeh, A. K., Sundaram, K. S., et al. (2024) · Journal of Extracellular Biology · doi:10.1002/jex2.70001 · Cited by 8
Zhang, K., Wang, Y., An, Q., Ji, H., Wu, D., Li, X., Suo, L., Zhang, C., & Dong, X. (2024) · Cell Proliferation · doi:10.1111/cpr.13785 · Cited by 10
“Notably, a clinical trial by RIKEN in 2013 is a global milestone as the first to investigate autologous hiPSC-RPE cell transplantation, highlighting the potential of hiPSC-based personalised medicine in clinical settings [7].”
Osete, J. R., Palomo, A. B. A., Codina-Pascual, M., Delgado‐Morales, R., Morán, S., Esteller, M., Farrera-Sal, M., Juan, M., Barado, A. B., Consiglio, A., et al. (2019) · Stem Cells · doi:10.1002/stem.2966 · Cited by 8
Human adult pluripotency: Facts and questions
Labusca, L. S., & Mashayekhi, K. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i1.1 · Cited by 10
Manipulating cell fate while confronting reproducibility concerns
Osterloh, J. M., & Mullane, K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.016 · Cited by 7
Evolution of Stem Cell Products in Medicine: Future of Off-the-Shelf Products
Pham, P. V., Nguyen, H. T., & Vu, N. B. (2018) · Stem cells in clinical applications · doi:10.1007/978-3-319-99328-7_6 · Cited by 9
Metadata
- Authors
- Souied, E. H., Pulido, J. S., & Staurenghi, G.
- Affiliations
- Université Paris-Est Créteil (FR)
- Mayo Clinic (US)
- University of Milan (IT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-24
- Volume
- 377
- Issue
- 8
- Pages
- 792-793
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3149364280
- Cited by
- 171
- References
- 3
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 15 · 2023: 18 · 2022: 23 · 2021: 22 · 2020: 32 · 2019: 25 · 2018: 16 · 2017: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- autologous stem cells, induced pluripotent stem cells, retinal cells, macular degeneration, cell therapy, retinal regeneration
- MeSH terms
- Humans, Macular Degeneration, Retina, Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.